ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-16

Study Completion Date

2022-07-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a non-inferiority (10% non-inferiority margin), study to assess the efficacy and safety of dolutegravir, DTG (50 mg once daily \[QD\]) administered in combination with tenofovir alafenamide fumarate, TAF (25 mg QD) and emtricitabine, FTC (200 mg QD) compared to DTG (50 mg QD) administered in combination with tenofovir disoproxil fumarate, TDF (300 mg QD) and FTC (200 mg QD) and compared to efavirenz, EFV (600 mg QD) administered in combination with TDF (300 mg QD) and FTC (200 mg QD) through 96 weeks in patients with HIV-1 starting first-line ART.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

NCT01968551

HIV-1 HIV Infections Acquired Immunodeficiency Syndrome

COMPLETED PHASE3

Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD

NCT04311944

HIV-1-infection

UNKNOWN NA

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

NCT03631732

HIV-1 Infection

COMPLETED PHASE3

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795

HIV-1 Infection

COMPLETED PHASE3

Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection

NCT02656511

HIV

ACTIVE_NOT_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open label randomised, non-inferiority (10% non-inferiority margin), phase 3 study to assess the efficacy and safety of DTG (50 mg once daily \[QD\]) administered in combination with TAF (25 mg QD) and FTC (200 mg QD) compared to DTG (50 mg QD) administered in combination with TDF (300 mg QD) and FTC (200 mg QD) and compared to EFV (600 mg QD) administered in combination with TDF (300 mg QD) and FTC (200 mg QD) through 96 weeks in patients with HIV-1 starting first-line ART.

Approximately 1110 male and female patients infected with HIV-1 who are eligible for first-line ART will be randomly assigned in a 1:1:1 ratio (approximately 370 patients per treatment group) to Treatment Group 1 (DTG + TAF + FTC) or Treatment Group 2 (DTG + TDF + FTC) or Treatment Group 3 (EFV + TDF + FTC). To ensure adequate representation of adolescents (12 - 18 years) in any treatment group, randomisation will be stratified according to age greater or less than 18 years. The study includes screening and baseline visits, 8 study visits from Week 4 to Week 84, and a preliminary end of study visit at Week 96.

The study will then take patients on Treatment Group 1 (DTG + TAF + FTC) or Treatment Group 2 (DTG + TDF + FTC) or Treatment Group 3 (EFV + TDF + FTC), who have completed 96 weeks successfully, and follow them to 192 weeks, with visits every 24 weeks after enrolment to 192 weeks. Study medication pill counts will be performed at each follow-up visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-1 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tenofovir Alafenamide

Descovy: Tenofivir alafenamide tablets 25mg daily, Emtricitabine 200mg daily

Group Type ACTIVE_COMPARATOR

Dolutegravir

Intervention Type DRUG

DTG 50mg Oral Tablet once daily

Tenofovir Alafenamide

Intervention Type DRUG

TAF/FTC 25/200mg Oral Tablet once daily

Dolutegravir

Dolutegravir 50mg daily, Truvada 500mg daily

Group Type ACTIVE_COMPARATOR

Dolutegravir

Intervention Type DRUG

DTG 50mg Oral Tablet once daily

Truvada

Intervention Type DRUG

Atripla

Atripla: Efavirenz 600mg daily, Tenofovir Disoproxil Fumarate 300mg daily, Emtricitabine 200mg daily

Group Type ACTIVE_COMPARATOR

Atripla

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dolutegravir

DTG 50mg Oral Tablet once daily

Intervention Type DRUG

Tenofovir Alafenamide

TAF/FTC 25/200mg Oral Tablet once daily

Intervention Type DRUG

Truvada

Intervention Type DRUG

Atripla

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tivicay Descovy TDF/FTC 300/200mg Oral Tablet EFV/TDF/FTC 600/200/300mg Oral Tablet

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 12 years and ≥ 40 kg
2. Documented laboratory diagnosis of infection with HIV-1 (positive enzyme-linked immunosorbent assay HIV-1 antibody test) at screening
3. Plasma HIV-1 RNA (VL) ≥ 500 copies/mL
4. All pre-existing medical or laboratory abnormalities must be deemed to be stable by the investigator prior to study enrolment
5. Calculated creatinine clearance (CrCl) \> 60 mL/min (Cockcroft-Gault formula) in \> 18 years old OR \> 80 mL/min (modified Cockcroft-Gault) in ≤ 18 years old
6. Ability to comprehend the full nature and purpose of the study, in the opinion of the investigator, and to comply with the requirements of the entire study.

To enrol in extension post-96 weeks:

Each patient must meet all of the following criteria to be enrolled in this study:

1. Previously enrolled on the ADVANCE study, and followed to week 96 (including those on post-trial access)
2. Ability to comprehend the full nature and purpose of the study, including the extended timeline, in the opinion of the investigator, and to comply with the requirements of the entire study.

Exclusion Criteria

1. Previously received more than 30 days of treatment with any form of antiretroviral therapy (ART) or
2. Received any antiretrovirals within the last 6 months
3. Women who are pregnant at the time of the screening or baseline visit
4. Active tuberculosis and/or are on antituberculous therapy at the time of the baseline visit
5. Taking and cannot discontinue prohibited concomitant medications listed in 7.3 at least 2 weeks prior to the baseline visit and for the duration of the study period
6. Clinically unstable, in the investigator's opinion
7. Current history of drug or alcohol abuse that, in the opinion of the investigator, may be an impediment to patient adherence to the protocol
8. Patients who participated in a study with an investigational drug within 60 days of screening or who are currently receiving treatment with any other investigational drug or device may be ineligible to participate. This is an investigator decision
9. Have a strong likelihood of relocating far enough to make access to the study site difficult
10. History or presence of allergy to the study drugs or their components
11. Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones); Child-Pugh C.

To enrol in extension post-96 weeks:

Patients meeting the following criteria will be excluded from the study:

1. HbA1c, lipids and blood pressures that are not responding to treatment, in the opinion of the investigator and in consultation with the principal investigator, justifying substitution of DTG or TAF
2. Clinically unstable, in the opinion of the investigator
3. Have a strong likelihood of relocating far enough to make access to the study site difficult.

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No